Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Apr 6;36(4):975–984. doi: 10.3904/kjim.2020.178

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 The Korean Association of Internal Medicine

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Comparison of responses to immune checkpoint inhibitors between patients with programmed death-ligand 1 (PD-L1) positivity in either archival or recent samples (PD-L1 [+, any] group) and those with negative PD-L1 status in both samples (PD-L1 [−/−] group). (A) The progression-free survival (PFS) was longer in the PD-L1 (+, any) group than in the PD-L1 (−/−) group (median PFS, 2.13 months vs. 1.07 months; hazard ratio [HR], 0.55; 95% confidence interval [CI], 0.30 to 1.03), but without statistical significance. (B) The overall survival (OS) was significantly longer in the PD-L1 (+, any) group than in the PD-L1 (−/−) group (median OS, 14.4 months vs. 4.93 months; HR, 0.43; 95% CI, 0.20 to 0.93).